Found 89 articles
Global Demand for Innovation Prevails Over Challenges of COVID-19: New Report From Evaluate Ltd.
“EvaluatePharma® World Preview 2020, Outlook to 2026” explores biopharma growth drivers, brakes and top performers
First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial
The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's investigational dual GIP and GLP-1 receptor agonist.
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is continuing to develop the 13 diabetes drugs it has in Phase I through Phase III trials, with data from various trials planned for release throughout the coming year.
The positions will be in manufacturing, assembly and packaging. The NC Department of Commerce approved the incentives this morning.
Vantage 2020 Preview: Strong Sales and Product Launches Set the Stage for Biopharma Growth, but Underlying Market Concerns Exist
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage 2020 Preview
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®
Results from several studies of Eli Lilly and Company's investigational dual GIP and GLP-1 receptor agonist, tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes.
Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio
Eli Lilly and Company will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, California.
Days after acquiring Loxo Oncology, Eli Lilly Chief Executive Officer David Ricks outlined projections for the new year and said that he, and other executive leaders, feel confident about the position that the company now finds itself in during a fireside chat at the J.P. Morgan Healthcare Confer...
Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting
2019 revenue is expected to be between $25.3 billion and $25.8 billion, representing mid-single-digit growth driven by volume from newer medicines, including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant and Lartruvo, as well as the recent launch of Emgality.